- Home
- STG vs CUE Comparison
STG vs CUE Comparison
Compare STG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- CUE
- Stock Information
- Founded
- STG 2003
- CUE 2014
- Country
- STG China
- CUE United States
- Employees
- STG N/A
- CUE N/A
- Industry
- STG Other Consumer Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- CUE Health Care
- Exchange
- STG Nasdaq
- CUE Nasdaq
- Market Cap
- STG 84.9M
- CUE 94.4M
- IPO Year
- STG 2018
- CUE 2018
- Fundamental
- Price
- STG $5.57
- CUE $1.04
- Analyst Decision
- STG
- CUE Strong Buy
- Analyst Count
- STG 0
- CUE 5
- Target Price
- STG N/A
- CUE $5.00
- AVG Volume (30 Days)
- STG 2.5K
- CUE 182.7K
- Earning Date
- STG 03-21-2025
- CUE 05-08-2025
- Dividend Yield
- STG N/A
- CUE N/A
- EPS Growth
- STG N/A
- CUE N/A
- EPS
- STG 4.57
- CUE N/A
- Revenue
- STG $292,030,936.00
- CUE $9,532,000.00
- Revenue This Year
- STG N/A
- CUE $73.11
- Revenue Next Year
- STG N/A
- CUE $11.02
- P/E Ratio
- STG $1.14
- CUE N/A
- Revenue Growth
- STG N/A
- CUE 149.53
- 52 Week Low
- STG $4.25
- CUE $0.45
- 52 Week High
- STG $11.35
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- STG 38.13
- CUE 35.54
- Support Level
- STG $6.15
- CUE $0.98
- Resistance Level
- STG $6.76
- CUE $1.13
- Average True Range (ATR)
- STG 0.35
- CUE 0.11
- MACD
- STG -0.13
- CUE -0.03
- Stochastic Oscillator
- STG 42.23
- CUE 12.39
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.